Furthermore, CRC patients with positive co-expression of both FOXQ1/Twist1 (P<0.001), or FOXQ1/CCL2 (P<0.01), Twist1/CCL2 (P<0.001), or CCL2/CD68 (P<0.05) had the shortest overall survival times compared with the corresponding single negative or double negative groups (Figure 7C). This evidence concerns the gene CD68 and colorectal carcinoma.